Cargando…

Dose-response relationship of stereotactic body radiotherapy for ultracentral tumor and comparison of efficacy with central tumor: a meta-analysis

BACKGROUND: Ultracentral (UC) tumors, a subset of central lung tumors defined as those that abut the proximal bronchial tree (PBT), have been contraindicated for stereotactic body radiotherapy (SBRT). The present meta-analysis evaluated the efficacy of SBRT for UC and central tumors, and dose-respon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rim, Chai Hong, Shin, In-Soo, Yoon, Won Sup, Park, Sunmin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481588/ https://www.ncbi.nlm.nih.gov/pubmed/32953504 http://dx.doi.org/10.21037/tlcr-20-503

Ejemplares similares

Stereotactic body radiotherapy (SBRT) for central and ultracentral node-negative lung tumors
por: Owen, Dawn, et al.
Publicado: (2020)

Progression of Pulmonary Function and Correlation with Survival Following Stereotactic Body Radiotherapy of Central and Ultracentral Lung Tumors
por: Regnery, Sebastian, et al.
Publicado: (2020)

Outcomes of stereotactic body radiotherapy 60 Gy in 8 fractions when prioritizing organs at risk for central and ultracentral lung tumors
por: Zhao, Yizhou, et al.
Publicado: (2020)

An optimal dose‐fractionation for stereotactic body radiotherapy in peripherally, centrally and ultracentrally located early‐stage non‐small lung cancer
por: Zarębska, Izabela, et al.
Publicado: (2023)

Magnetic resonance guided adaptive stereotactic body radiotherapy for lung tumors in ultracentral location: the MAGELLAN trial (ARO 2021-3)
por: Regnery, Sebastian, et al.
Publicado: (2022)

Ten fraction hypofractionated stereotactic body radiotherapy for the management of ultracentral lung tumors: a retrospective analysis of dosimetry, outcomes, and toxicity
por: Rock, Crosby, et al.
Publicado: (2023)

External validation of pulmonary radiotherapy toxicity models for ultracentral lung tumors
por: Chen, Ishita, et al.
Publicado: (2022)

Exceeding Radiation Dose to Volume Parameters for the Proximal Airways with Stereotactic Body Radiation Therapy Is More Likely for Ultracentral Lung Tumors and Associated with Worse Outcome
por: Farrugia, Mark, et al.
Publicado: (2021)

Is the Concurrent Use of Sorafenib and External Radiotherapy Feasible for Advanced Hepatocellular Carcinoma? A Meta-Analysis
por: Rim, Chai Hong, et al.
Publicado: (2021)

Magnetic Resonance-Guided Stereotactic Body Radiation Therapy/Hypofractionated Radiation therapy for Metastatic and Primary Central and Ultracentral Lung Lesions
por: Sandoval, Maria L., et al.
Publicado: (2023)

Stereotactic ablative radiotherapy of 60 Gy in eight fractions is safe for ultracentral non‐small cell lung cancer
por: Yang, Dan, et al.
Publicado: (2020)

Simulating the Potential of Model-Based Individualized Prescriptions for Ultracentral Lung Tumors
por: Chen, Ishita, et al.
Publicado: (2023)

Indications of external radiotherapy for hepatocellular carcinoma from updated clinical guidelines: Diverse global viewpoints
por: Park, Sunmin, et al.
Publicado: (2020)

Where is clinical research for radiotherapy going? Cross-sectional comparison of past and contemporary phase III clinical trials
por: Park, Sunmin, et al.
Publicado: (2020)

Stereotactic body radiotherapy for central lung tumors, yes we can!
por: Korzets ceder, Yasmin, et al.
Publicado: (2018)

Variation of heart and lung radiation doses according to setup uncertainty in left breast cancer
por: Park, Sunmin, et al.
Publicado: (2021)

Survival and Prognostic Factors of Ultra-Central Tumors Treated with Stereotactic Body Radiotherapy
por: Salvestrini, Viola, et al.
Publicado: (2022)

Stereotactic ablative body radiotherapy with a central high dose using CyberKnife for metastatic lung tumors
por: Hayashi, Kazuhiko, et al.
Publicado: (2023)

Stereotactic Body Radiotherapy for the Treatment of Renal Tumors()
por: Hanzly, Michael, et al.
Publicado: (2014)

Salvage External Beam Radiotherapy after Incomplete Transarterial Chemoembolization for Hepatocellular Carcinoma: A Meta-Analysis and Systematic Review
por: Yang, Dae Sik, et al.
Publicado: (2021)

Analysis of Biologically Equivalent Dose of Stereotactic Body Radiotherapy for Primary and Metastatic Lung Tumors
por: Park, Sungkwang, et al.
Publicado: (2014)

Stereotactic body radiotherapy for central lung tumors: Finding the balance between safety and efficacy in the “no fly” zone
por: Ahmed, Nissar, et al.
Publicado: (2018)

Benefits of Local Treatment Including External Radiotherapy for Hepatocellular Carcinoma with Portal Invasion
por: Lee, Han Ah, et al.
Publicado: (2021)

Oncologic Benefit of Adjuvant Chemoradiation after D2 Gastrectomy: A Stepwise Hierarchical Pooled Analysis and Systematic Review
por: Rim, Chai Hong, et al.
Publicado: (2020)

Stereotactic MR-Guided Online Adaptive Radiation Therapy (SMART) for Ultracentral Thorax Malignancies: Results of a Phase 1 Trial
por: Henke, Lauren E., et al.
Publicado: (2018)

Long term results of single high dose Stereotactic Body Radiotherapy in the treatment of primary lung tumors
por: Nicosia, Luca, et al.
Publicado: (2019)

Safety of high-dose-rate stereotactic body radiotherapy
por: Stieb, Sonja, et al.
Publicado: (2015)

Stereotactic Body Radiotherapy for Small Lung Tumors in the University of Tokyo Hospital
por: Yamashita, Hideomi, et al.
Publicado: (2014)

Choice of immobilization of stereotactic body radiotherapy in lung tumor patient by BMI
por: Chen, Guofu, et al.
Publicado: (2019)

Interfractional Variations of Tumor Centroid Position and Tumor Regression during Stereotactic Body Radiotherapy for Lung Tumor
por: Sun, Yanan, et al.
Publicado: (2014)

Stereotactic body radiation therapy for centrally-located lung tumors
por: SHEN, GE, et al.
Publicado: (2014)

Stereotactic body radiotherapy for centrally-located lung tumors with 56 Gy in seven fractions: A retrospective study
por: Aoki, Shuri, et al.
Publicado: (2018)

Stereotactic Radiosurgery and Stereotactic Radiotherapy for Malignant Skull Base Tumors
por: Mori, Yoshimasa, et al.
Publicado: (2020)

Dose–effect relationship of stereotactic body radiotherapy in non-small cell lung cancer patients
por: Li, Fei, et al.
Publicado: (2022)

Multi-center evaluation of dose conformity in stereotactic body radiotherapy
por: Lee, Jonny, et al.
Publicado: (2019)

Efficacy and Dose-Response Relationship of Stereotactic Body Radiotherapy for Abdominal Lymph Node Metastases from Hepatocellular Carcinoma
por: Wang, Yuting, et al.
Publicado: (2023)

Radiation-induced organizing pneumonia after stereotactic body radiotherapy for lung tumor
por: Ochiai, Satoru, et al.
Publicado: (2015)

Feasibility of Adaptive MR-guided Stereotactic Body Radiotherapy (SBRT) of Lung Tumors
por: Padgett, Kyle R, et al.
Publicado: (2018)

Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients
por: König, Laila, et al.
Publicado: (2020)

Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy
por: Grimm, Jimm, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_cg5sp7k6gq4r71n2o94jl37ifn